Prothena Corp PLC (PRTA)
54.98
-2.14 (-3.75%)
USD |
NASDAQ |
Jan 30, 16:00
54.98
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 2.660B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 81.62% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 514.07 |
Price to Book Value | 6.573 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.00 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 90.85% |
News
Headline
Wire
Time (ET)
SA Breaking News
01/27 12:04
Yahoo
01/15 09:01
MT Newswires
01/13 08:03
SA Breaking News
01/06 15:19
MT Newswires
12/21 09:35
Events
DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
02/17/2023* | -- | Results | Q4 2022 | -- | -0.45 | -- | |
02/17/2023* | 16:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
11/03/2022 | -- | Results | Q3 2022 | -0.97 | -0.62 | -56.70% | |
08/08/2022 | -- | Results | Q2 2022 | -0.88 | -0.53 | -66.77% | |
05/05/2022 | -- | Results | Q1 2022 | -0.78 | -0.64 | -22.28% | |
02/17/2022 | 16:30 EST | Earnings Call | Q4 2021 | -- | -- | -- | |
02/17/2022 | -- | Results | Q4 2021 | -0.71 | -0.44 | -62.83% | |
11/04/2021 | -- | Results | Q3 2021 | 2.13 | 2.24 | -4.70% |
*Estimated Date/Time
Earnings
Profile
Edit
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). |
URL | https://www.prothena.com |
Investor Relations URL | https://ir.prothena.com/ |
HQ State/Province | N/A |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Mid Cap/Blend |
Next Earnings Release | Feb. 17, 2023 (est.) |
Last Earnings Release | Nov. 03, 2022 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Dividends
Dividend Per Share (TTM) | -- |
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
Yield to Market | 0.00 |
Yield to Sector | 0.00 |
Yield to Industry | 0.00 |
Last Dividend Amt. | -- |
Dividend Frequency | -- |
Last Ex-Dividend Date | -- |
Yield (TTM) | 0% |
Forward Yield | -- |
Payout Ratio | 0.00% |
Cash Payout Ratio | -- |
Consistent Payer (5Y) | No |
Consistent Growth (5Y) | No |
Risk Info
Total Returns Comparison
Annual Total Returns Versus Peers
As of January 27, 2023.
Fundamentals
Revenue (TTM) | 5.154M |
Total Expenses (TTM) | 169.73M |
Net Income (TTM) | -156.48M |
Total Assets (Quarterly) | 554.44M |
Total Liabilities (Quarterly) | 149.79M |
Shareholders Equity (Quarterly) | 404.65M |
Ratings
Profile
Edit
Prothena Corp PLC is a biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating rare neurodegenerative and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004). |
URL | https://www.prothena.com |
Investor Relations URL | https://ir.prothena.com/ |
HQ State/Province | N/A |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Mid Cap/Blend |
Next Earnings Release | Feb. 17, 2023 (est.) |
Last Earnings Release | Nov. 03, 2022 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Risk Info
Ownership
Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Other Resources
Whale Wisdom | 13F Filings |
Seeking Alpha | Call Transcripts |
Nasdaq | Insider Trading |
Nasdaq | Institutional Ownership |
Nasdaq | Option Chain |
SEC | SEC Filings |
PRTA Tweets |